Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (GENIL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (GENIL) has a cash flow conversion efficiency ratio of 0.018x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (TL174.79 Million ≈ $3.91 Million USD) by net assets (TL9.76 Billion ≈ $218.58 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See GENIL defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Rukun Raharja Tbk
JK:RAJA
|
0.041x |
|
Omada Health, Inc. Common Stock
NASDAQ:OMDA
|
0.047x |
|
Hangzhou Sunrise Technology Co Ltd
SHE:300360
|
0.057x |
|
Dios Fastigheter AB
ST:DIOS
|
0.006x |
|
Limbach Holdings Inc
NASDAQ:LMB
|
-0.040x |
|
GlaxoSmithKline PLC
LSE:GSK
|
0.141x |
|
MFA Financial Inc
NYSE:MFA
|
0.040x |
|
ZKTECO Co. Ltd. A
SHE:301330
|
N/A |
Annual Cash Flow Conversion Efficiency for Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (2018–2024)
The table below shows the annual cash flow conversion efficiency of Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Gen Ilac ve Saglik Urunleri Sanayi ve Ti.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | TL7.31 Billion ≈ $163.67 Million |
TL1.99 Billion ≈ $44.65 Million |
0.273x | +647.34% |
| 2023-12-31 | TL7.01 Billion ≈ $157.11 Million |
TL256.05 Million ≈ $5.73 Million |
0.037x | +533.85% |
| 2022-12-31 | TL2.80 Billion ≈ $62.81 Million |
TL16.15 Million ≈ $361.73K |
0.006x | -95.34% |
| 2021-12-31 | TL1.28 Billion ≈ $28.76 Million |
TL158.83 Million ≈ $3.56 Million |
0.124x | -30.18% |
| 2020-12-31 | TL557.36 Million ≈ $12.48 Million |
TL98.74 Million ≈ $2.21 Million |
0.177x | -73.86% |
| 2019-12-31 | TL245.48 Million ≈ $5.50 Million |
TL166.39 Million ≈ $3.73 Million |
0.678x | +270244.50% |
| 2018-12-31 | TL112.59 Million ≈ $2.52 Million |
TL28.23K ≈ $632.21 |
0.000x | -- |
About Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS
Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi, a pharmaceutical company, manufactures and supplies products to treat rare diseases and disorders worldwide. The company offers its products in various areas, such as neurology, endocrinology, nephrology, oncology, hematology, and pediatric. Gen Ilac Ve Saglik Urunleri Sanayi Ve Ticaret Anonim Sirketi has collaboration with Sulfateq BV… Read more